The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review
- 206 Downloads
Purpose of Review
Osteoporosis in axial spondyloarthritis may be modified by therapy. The purpose of this systematic review is to describe (i) the effect of TNFi on BMD, (ii) the effect of secukinumab on BMD, and (iii) the effect of secukinumab on radiographic disease progression in axSpA.
We searched PubMed, Embase, and Cochrane using the following retrieval languages: spondyloarthritis, ankylosing spondylitis, TNF, IL-17, x-rays, and osteoporosis. Twenty-nine studies were included; 27 re: TNFi and BMD, and 2 re: IL-17 blockers and x-ray progression. TNFi over 2–4 years increased BMD of the lumbar spine (3.2–14.9%) and hip (2.26–4.7%) without reducing vertebral fractures. Secukinumab reduced radiographic progression; none (73%) and minimal (79%) at 4 years. No data on IL-17 blockade and bone were found.
TNFi therapy improves bone density but not vertebral fracture rates. Secukinumab improves symptoms and may slow radiographic progression. Data is lacking regarding the effects of secukinumab on BMD and fractures. These are important questions which may impact the choice of therapy.
KeywordsAxial spondyloarthritis Ankylosing spondylitis Osteoporosis Bone density TNF inhibitors IL-17 Secukinumab Radiographic progress Vertebral fracture
Tumor necrosis factor (TNF) inhibitor
Randomized control trial
Preferred reporting items for systematic review and meta-analysis
Modified Stoke Ankylosing Spondylitis Spinal Score
American College of Rheumatology
Occiput to wall
Bath Ankylosing Spondylitis Functional Index
The authors thank Haley Tornberg—research assistant.
DA, EMS, and SMG contributed to the conception and design of the review and assessed all papers, data extraction, and quality assessment. DA, EMG, RG, and SMG performed the literature search. DA drafted the paper; EMS and SMG revised the article for important intellectual content. All authors gave final approval of the version to be published.
Compliance with Ethical Standards
Conflict of Interest
Dr. Goodman reports grants from Novartis, personal fees from Novartis, personal fees from Pfizer, personal fees from UCB, grants from Horizon, outside the submitted work.
Dr. Ashany reports grants from Novartis, outside the submitted work.
Emily M. Stein and Rie Goto declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Ethics Approval and Consent to Participate
Consent for Publication
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, Kallenberg CG, et al. The effect of three years of TNFalpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2012;14(2):R98.Google Scholar
- 7.Durnez A, Paternotte S, Fechtenbaum J, Landewe RB, Dougados M, Roux C, et al. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol. 2013;40(10):1712–8.Google Scholar
- 8.Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54.Google Scholar
- 9.Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M, et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 2017;69(7):1011–9.Google Scholar
- 10.Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. Ann Rheum Dis. 2018;77(1):63–9.Google Scholar
- 13.Wellcome Trust Case Control C, Australo-Anglo-American spondylitis C, Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329–37.Google Scholar
- 14.Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76.Google Scholar
- 15.Tseng HW, Pitt ME, Glant TT, McRae AF, Kenna TJ, Brown MA, Pettit AR, Thomas GP: Inflammation-driven bone formation in a mouse model of ankylosing spondylitis: sequential not parallel processes. Arthritis Res Ther 2016, 18:0.Google Scholar
- 16.• Mansoori MN, Shukla P, Singh D. Combination of PTH (1–34) with anti-IL17 prevents bone loss by Inhibiting IL-17/ N-cadherin mediated disruption of PTHR1/LRP-6 interaction. Bone. 2017;105:226–36 This study investigates the mechanism of action by which IL-17 promotes bone loss and provides data demonstrating that the bone loss occurs through up-regulation of N-cadherin and inhibition of wnt signaling. This provides a rationale for the hypothesis that blockade of IL-17 may be beneficial in preventing osteoporosis. CrossRefGoogle Scholar
- 17.Tyagi AM, Mansoori MN, Srivastava K, Khan MP, Kureel J, Dixit M, et al. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29(9):1981–92.Google Scholar
- 19.Azizieh F, Raghupathy R, Shehab D, Al-Jarallah K, Gupta R: Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause (New York, NY) 2017, 24(9):1057–1064.Google Scholar
- 20.•• Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomized phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070–7 This study describes the results of the Phase 3 secukinumab study in AS demonstrating both improvement in AS signs and symptoms through 2 years of therapy as well as low mean progression of spinal radiographic progression. Google Scholar
- 21.Braun J, Baraliakos X, Deodhar AA, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B: Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Arhtritis Rheumatol 2017, 69(suppl 10).Google Scholar
- 24.Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.Google Scholar
- 29.• van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE. Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol. 2016;43(4):758–64 This study highlights the dichotomy of increased bone density at the hip and spine with the anti-TNF agent Etanercept in AS patients but also reports increased incidence of vertebral fracture in this group of patients. CrossRefGoogle Scholar
- 30.Maas F, Spoorenberg A, Brouwer E, Schilder AM, Chaudhry RN, Wink F, et al. Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-alpha blocking therapy. Clin Exp Rheumatol. 2016;34(2):191–9.Google Scholar
- 31.Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.Google Scholar
- 33.Beek K, van der Weijden M, Lems W, van Denderen W, Nurmohamed M, Van der Horst-Buinsma I. Long-term effects of TNF-alpha inhibitors on bone mineral density and the incidence of vertebral fractures in patients with ankylosing spondylitis. Arthritis Rheum. 2017;69(suppl 10).Google Scholar
- 34.Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;382(9906):1705–13.Google Scholar
- 35.Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408–12.Google Scholar
- 36.Braun J, Buehring, B., Baraliakos, X., Gensler, LS., Porter, B., Shete, A., Quebe-Fehling, E., Haemmerle S.: Bone mineral density and serum biomarkers of bone turnover in ankylosing spondylitis patients treated with Secukinumab: 2-year data from the pivotal phase 3 study. Arthritis Rheum 2018, 70(S10).Google Scholar